Suzhou Terrill Pharmaceutical

Suzhou Thery Pharmaceutical is an R&D-driven pharmaceutical company specializing in specialty active pharmaceutical ingredients (APIs) and high-end formulations. Founded in 2010 and headquartered in Suzhou, China, the company has established an integrated platform spanning research, quality management, commercial manufacturing, and marketing. Its pipeline includes small molecule drugs and peptide therapeutics, with key programs such as a semaglutide biosimilar in Phase 3 development for obesity and overweight, and generic nilotinib for chronic myeloid leukemia. Thery Pharmaceutical operates multiple cGMP-compliant manufacturing facilities in Suzhou and Shandong, serving both domestic and international markets.